
Oct 3
On the eve of this year’s DPharm conference, TransCelerate hosted its first Digital Data Flow Discovery Day in Boston. The goal of the event was to raise awareness, exchange knowledge, and convene stakeholders from around the R&D industry to demonstrate the implementation of its Digital Data Flow (DDF) solutions, the Unified Study Definitions Model (USDM), and the Study Definitions Repository (SDR).
Clinical protocol design is generally an electronic form of paper and is limited in having a structured data format that other systems can easily leverage. In today’s data-driven world, now is the time to seize the opportunity of a digital-first approach focusing on “Write once, use many times.”
Over the past three years, TransCelerate’s DDF Initiative, in collaboration with CDISC, has delivered a foundational Unified Study Definitions Model (USDM), an open-source Study Definitions Repository (SDR) Reference Implementation aimed at supporting the widespread use of digital protocols across the industry, and accompanying CDISC standards. Earlier this year, Versions 2.0 of the CDISC USDM and SDR were released with key enhancements, including automated electronic data capture set-up and common protocol template export.
“I know change is coming and I want to be part of the dialogue”
This face-to-face event brought together 17 TransCelerate Member Companies, seven clinical solution providers applying one of the DDF solutions, and other key industry stakeholders from CDISC and the HL7 FHIR Vulcan Accelerator for an interactive experience to raise awareness and exchange knowledge around the implementation of the DDF solutions.
To create a robust experience, the DDF Discovery Day included explorations of practical applications of the DDF solutions, moderated discussions of transformational enablers and potential hurdles, and presentations on the future roadmap for DDF as the initiative is converging with many standards-related efforts in the ecosystem, including the advancement of ICH M11 CeSHarP and research-to-care interoperability through the Vulcan FHIR Accelerator under HL7.
The day was split between meaningful group discussions and workshops and one-on-one engagements. The agenda allowed multiple opportunities for participants to exchange perspectives, discuss use cases, and learn about tools and resources. The audience was highly engaged, with TransCelerate members rotating through the provider showcase exhibits and learning about the landscape of options. It was apparent that the audience recognized that putting DDF into practice is now a real and present opportunity. Attendees shared their enthusiasm with each other, sharing sentiments such as,
To close out the day, attendees gathered for roundtable discussions and shared insights on implementing this type of digital transformation. Some common themes stood out:
All in all, the first-ever DDF Discovery Day was a huge success, with future events planned. As a result of the event, it became apparent that DDF implementation is further along than expected. A post-event survey indicated that all respondents are interested in attending a future event.
Thank you to everyone who participated. A post-event summary and conclusions readout will be published soon on the DDF site. To learn more about how to get involved or approach it in your organization, visit the Digital Data Flow GitHub page.
In ACRO and TransCelerate BioPharma’s latest collaboration, Cris McDavid (Senior Director, Global Clinical Operations, Parexel) and Tashan Mistree (Senior Director, Business Operations, Office of Chief Medical Officer, GSK) join this week’s episode to discuss the impact of ICH E6(R3) from their different vantage points in the clinical research industry. Listen to the podcast by Cris McDavid and Tashan Mistree…
In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate…
For decades, women were significantly underrepresented in clinical trials. Recent years have seen improvement, but there are lingering gaps in our collective understanding of how therapies work across sexes, life stages, health conditions and care settings. Read the full article by Jeneen Donadeo from PharmaTimes here.